Retrospective multicenter study defines CDK4/6 inhibitor-induced liver injury in a large cohort, suggesting areas for standardized management.
Key Points
This research aims to evaluate the incidence, clinical features, severity, and management of drug-induced liver injury (DILI) associated with CDK4/6 inhibitors.
Retrospective multicenter study involving patients with grade-2 or higher DILI while on CDK4/6 inhibitors from January 2018 to December 2022.
DILI severity assessed using CTCAEv5 and DILI-IEWG criteria.
Data analyzed included incidence rates and biochemical results.
Among 2,222 patients, 100 (4.5%) developed DILI, with higher incidence observed for ribociclib (8.3%) and abemaciclib (6.7%) compared to palbociclib (1.4%).
Most DILI cases were grade 2 or 3 and mild; moderate DILI was noted with all drugs.
DILI recurred in 28% upon rechallenge with CDK4/6 inhibitors, suggesting a need for standardized management.
Cite This Study
Riveiro‐Barciela et al. (2026) studied this question.